Video

More Lupus Drugs Are in the Pipeline


 

The new drug pipeline holds some promising therapies for lupus, according to Dr. Maureen McMahon, a rheumatologist at UCLA. But new drug development and FDA approval take time. Until then, lupus patients have Benlysta, the first drug to be approved for lupus in 50 years as well as the reliable, tried-and-true antimalarial drug hydroxychloroquine that has served them so well. This interview was conducted at the 5th Annual Perspectives in Rheumatic Diseases Seminar.

Recommended Reading

Lupus Severity May Contribute Significantly to Heart Damage
MDedge Rheumatology
Genotypes in ANCA-Associated Vasculitis May Guide Therapy
MDedge Rheumatology
Chloroquine Eyed for Treating Metabolic Syndrome
MDedge Rheumatology
Serious CNS Events in Lupus Seen in Only 4% of Cases
MDedge Rheumatology
Collagenase Might Be a First-Line Treatment for Dupuytren's Contractures
MDedge Rheumatology
Biopsy Must Guide Lupus Nephritis Management
MDedge Rheumatology
Giant Cell Arteritis: Temporal Artery Biopsy Trumps ACR Criteria
MDedge Rheumatology
Rheumatologic Serologies Can Be a Confounding Quagmire
MDedge Rheumatology
Pregnancy in Lupus Poses Unique Challenges
MDedge Rheumatology
Antimalarial Response in CLE Takes Time
MDedge Rheumatology